

Item 2.02 Results of Operations and Financial Condition.

On April 25, 2013, Emergent BioSolutions Inc. issued a press release, which is furnished as Exhibit 99 to this Current Report on Form 8-K. The statements in the press release reaffirming first quarter 2013 revenue guidance are incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On April 25, 2013, Emergent BioSolutions Inc. issued a press release, which is furnished as Exhibit 99 to this Current Report on Form 8-K. The statements in the press release reaffirming 2013 annual revenue and net income guidance are incorporated herein by reference.

Item 8.01 Other Events.

On April 25, 2013, Emergent BioSolutions Inc. issued a press release announcing that it has entered into an asset purchase agreement to acquire the Healthcare Protective Products Division of Bracco Diagnostics Inc.

A copy of the press release is attached as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference, except for the statements reaffirming first quarter 2013 revenue guidance and 2013 annual revenue and net income guidance.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99 Press Release issued by Emergent BioSolutions Inc. on April 25, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 25, 2013 EMERGENT
BIOSOLUTIONS
INC.
By: /s/ Jay G. Reilly
Jay G. Reilly
General Counsel